<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228692</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0686</org_study_id>
    <secondary_id>2019-A02583-54</secondary_id>
    <nct_id>NCT04228692</nct_id>
  </id_info>
  <brief_title>Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery</brief_title>
  <official_title>Evaluation of the Benefits of Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptomatic endometriosis can be responsible for urinary problems as well as symptoms of&#xD;
      clinical bladder hyperactivity and/or symptoms of bladder pain before or during miction that&#xD;
      can persist after bladder voiding. Whereas urinary problems can predate surgery due to the&#xD;
      endometrial lesions themselves, the surgery can also have functional consequences for urinary&#xD;
      function, specifically when there is trauma (incisions, per-operative coagulation) to the&#xD;
      inferior hypogastric nerve fibers and/or to the hypogastric plexus.&#xD;
&#xD;
      The incidence of post-surgery urinary symptoms could be as high as 30%. The incidence of&#xD;
      voiding problems and specifically of non-obstructive voiding dysfunction can be observed in&#xD;
      17,5% of cases of patients 1-month post-surgery for deep colorectal endometriosis, and&#xD;
      persists in 4,8% of women after 12 months.&#xD;
&#xD;
      The gold standard for treatment of voiding problems consists of self-catheterization, as is&#xD;
      the case for all non-obstructive voiding dysfunction symptoms. This procedure considerably&#xD;
      impacts quality of life. The proper and complete voiding of the bladder remains essential in&#xD;
      order to avoid recurring urinary tract infections and pelvic static disorder.&#xD;
&#xD;
      In the case of persistent dysuria, the use of self-catheterization is necessary in 21% of&#xD;
      patients after surgery for deep endometriosis, for an average duration of 85 days. To date,&#xD;
      few studies have explored the management of post-operative urinary complications after&#xD;
      surgery for deep endometriosis. Pharmaceutical alternatives (alpha-blockers,&#xD;
      anticholinergics, benzodiazepines) have not proven effective and sometimes cause side&#xD;
      effects. However promising alternative treatments are being developed, specifically the&#xD;
      neuromodulation of the sacral root. This procedure has been shown effective in the treatment&#xD;
      of non-obstructive voiding dysfunction; however, it remains an invasive treatment that has&#xD;
      its load of complications and undesirable side-effects. A recent study reports favorable&#xD;
      results for the use of sacral neuromodulation in the case of persistent incomplete voiding&#xD;
      following surgery for deep colorectal endometriosis. Some studies have also suggested that&#xD;
      percutaneous posterior tibial nerve stimulation (PTN) could also be a treatment alternative.&#xD;
      The advantage of this procedure is that it is non-invasive and less constraining. No study&#xD;
      has yet evaluated whether PTN could also be used to treat patients with persistent voiding&#xD;
      dysfunction following surgery for deep endometriosis.&#xD;
&#xD;
      Our study, conducted in the gynecologic department of Croix ROUSSE Hospital, Lyon (France),&#xD;
      evaluates PTN as a new treatment option for post-operative voiding dysfunction in women who&#xD;
      suffer from deep endometriosis. Our aim is to prove that the use of PTN can reduce the&#xD;
      duration of self-catheterization by 50% when compared to self-catheterization only.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of 50% of total duration of self-catheterization in the self-catheterization + PTN group</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Comparison of total numbers of days of self-catheterization between the 2 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of self-catheterizations per day</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post voiding residual urine volume (PVR)</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of PVR&gt; 50% of spontaneous miction</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of PTN</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>sensation of small electrical discharges, skin reactions next to the electrodes will be notified by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of sessions of PTN per week</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of each session of PTN</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Endometriosis</condition>
  <condition>Dysuria</condition>
  <arm_group>
    <arm_group_label>Self-catheterization only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior tibial nerve stimulation + self-catheterization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.&#xD;
Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self-catheterization only</intervention_name>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.</description>
    <arm_group_label>Self-catheterization only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Posterior tibial nerve stimulation + self-catheterization</intervention_name>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.&#xD;
Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.</description>
    <arm_group_label>Posterior tibial nerve stimulation + self-catheterization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are eligible for the French public healthcare system&#xD;
&#xD;
          -  Patients who have given their consent for this research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cognitive, psychiatric or motor disturbances, that do not allow for&#xD;
             independent use of the device&#xD;
&#xD;
          -  Patients who do not speak French&#xD;
&#xD;
          -  Patients who have had a surgery (bladder or ureters) for endometriosis or any other&#xD;
             reason.&#xD;
&#xD;
          -  Patients who were participating in another ongoing study, or within the exclusion time&#xD;
             stipulated by another study (at the discretion of the investigator)&#xD;
&#xD;
          -  Patients unable to give their consent (protected by law: under guardianship /&#xD;
             trusteeship)&#xD;
&#xD;
          -  Patients who are taking a pharmaceutical treatment for urological problem&#xD;
             (anticholinergics, alpha-blockers, prostaglandin)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients with a pacemaker&#xD;
&#xD;
          -  Patients with dermatological problem in the area where the device's electrodes have to&#xD;
             be installed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie WAREMBOURG, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie WAREMBOURG, Dr</last_name>
    <phone>4.72.07.19.36</phone>
    <phone_ext>+33</phone_ext>
    <email>sophie.warembourg@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie WAREMBOURG, Dr</last_name>
      <phone>4.72.07.19.36</phone>
      <phone_ext>+33</phone_ext>
      <email>sophie.warembourg@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep endometriosis surgery</keyword>
  <keyword>voiding dysfunction</keyword>
  <keyword>self-catheterization</keyword>
  <keyword>posterior tibial nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Dysuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

